Compare Stocks: ROIV, MRNA, REGN, and NTRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MRNA Moderna	$202.63 -17.6%	$170.05	$22.28 ▼ $254.48	$98.14B	1.09	17.80 million shs	49.76 million shs
NTRA Natera	$401.37 -2.9%	$365.45	$181.00 ▼ $437.41	$59.59B	1.5	1.67 million shs	1.61 million shs
REGN Regeneron Pharmaceuticals	$819.09 +1.7%	$791.83	$572.75 ▼ $859.34	$82.95B	0.16	692,734 shs	852,262 shs
ROIV Roivant Sciences	$37.45 +1.8%	$36.61	$17.89 ▼ $42.50	$26.58B	1.1	6.01 million shs	13.45 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MRNA Moderna	-17.57%	-14.32%	+10.99%	+274.75%	+654.67%
NTRA Natera	-2.91%	-0.84%	+2.68%	+53.20%	+113.47%
REGN Regeneron Pharmaceuticals	+1.67%	+2.86%	+1.89%	+24.86%	+40.08%
ROIV Roivant Sciences	+1.77%	+10.02%	-2.01%	+6.97%	+108.52%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MRNA Moderna	$202.63 -17.6%	$170.05	$22.28 ▼ $254.48	$98.14B	1.09	17.80 million shs	49.76 million shs
NTRA Natera	$401.37 -2.9%	$365.45	$181.00 ▼ $437.41	$59.59B	1.5	1.67 million shs	1.61 million shs
REGN Regeneron Pharmaceuticals	$819.09 +1.7%	$791.83	$572.75 ▼ $859.34	$82.95B	0.16	692,734 shs	852,262 shs
ROIV Roivant Sciences	$37.45 +1.8%	$36.61	$17.89 ▼ $42.50	$26.58B	1.1	6.01 million shs	13.45 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MRNA Moderna	-17.57%	-14.32%	+10.99%	+274.75%	+654.67%
NTRA Natera	-2.91%	-0.84%	+2.68%	+53.20%	+113.47%
REGN Regeneron Pharmaceuticals	+1.67%	+2.86%	+1.89%	+24.86%	+40.08%
ROIV Roivant Sciences	+1.77%	+10.02%	-2.01%	+6.97%	+108.52%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MRNA Moderna	2.12	Hold	$103.95	-48.70% Downside
NTRA Natera	2.79	Moderate Buy	$379.20	-5.52% Downside
REGN Regeneron Pharmaceuticals	2.77	Moderate Buy	$846.28	3.32% Upside
ROIV Roivant Sciences	2.79	Moderate Buy	$45.64	21.86% Upside

Current Analyst Ratings Breakdown

Latest ROIV, MRNA, REGN, and NTRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/22/2026	NTRA Natera	Roth Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$475.00
10/21/2026	ROIV Roivant Sciences	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/21/2026	MRNA Moderna	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/21/2026	MRNA Moderna	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Hold	$40.00 ➝ $90.00
10/21/2026	REGN Regeneron Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$960.00 ➝ $980.00
10/19/2026	NTRA Natera	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$375.00 ➝ $500.00
10/19/2026	REGN Regeneron Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$854.00 ➝ $865.00
10/16/2026	NTRA Natera	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
10/15/2026	NTRA Natera	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	MRNA Moderna	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$120.00 ➝ $137.00
10/15/2026	REGN Regeneron Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Neutral ➝ Buy	$660.00 ➝ $978.00

(Data available from 10/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MRNA Moderna	$1.94B	41.61	N/A	N/A	$22.14 per share	9.15
NTRA Natera	$2.31B	25.09	N/A	N/A	$12.38 per share	32.42
REGN Regeneron Pharmaceuticals	$14.34B	5.88	$42.68 per share	19.19	$295.66 per share	2.77
ROIV Roivant Sciences	$8.26M	3,274.93	N/A	N/A	$7.35 per share	5.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MRNA Moderna	-$2.82B	-$7.99	N/A	N/A	N/A	-141.43%	-28.30%	-19.39%	11/6/2026 (Estimated)
NTRA Natera	-$208.16M	-$1.36	N/A	N/A	N/A	-7.11%	-11.38%	-7.87%	11/5/2026 (Estimated)
REGN Regeneron Pharmaceuticals	$4.50B	$40.46	20.24	15.47	1.37	27.86%	13.47%	10.34%	10/30/2026 (Estimated)
ROIV Roivant Sciences	-$299.77M	-$0.53	N/A	N/A	N/A	-3,534.96%	-22.94%	-21.53%	11/9/2026 (Estimated)

Latest ROIV, MRNA, REGN, and NTRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q2 2027	ROIV Roivant Sciences	-$0.3671	N/A	N/A	N/A	$3.74 million	N/A
11/6/2026	Q3 2026	MRNA Moderna	-$1.11	N/A	N/A	N/A	$891.34 million	N/A
11/5/2026	Q3 2026	NTRA Natera	-$0.2812	N/A	N/A	N/A	$707.67 million	N/A
10/30/2026	Q3 2026	REGN Regeneron Pharmaceuticals	$16.20	N/A	N/A	N/A	$4.56 billion	N/A
8/7/2026	Q1 2027	ROIV Roivant Sciences	-$0.2996	-$0.26	+$0.0396	-$0.26	$2.06 million	$1.44 million
8/6/2026	Q2 2026	NTRA Natera	-$0.4939	-$0.47	+$0.0239	-$0.47	$661.24 million	$752.75 million
7/31/2026	Q2 2026	MRNA Moderna	-$2.03	-$1.97	+$0.06	-$1.97	$102.93 million	$145.00 million
7/30/2026	Q2 2026	REGN Regeneron Pharmaceuticals	$10.16	$14.29	+$4.13	$12.23	$3.82 billion	$4.29 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
NTRA Natera	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$3.76	0.46%	N/A	9.29%	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Latest ROIV, MRNA, REGN, and NTRA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2026	REGN Regeneron Pharmaceuticals	quarterly	$0.94	0.46%	8/18/2026	8/18/2026	8/31/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MRNA Moderna	0.09	2.29	2.18
NTRA Natera	N/A	3.00	2.85
REGN Regeneron Pharmaceuticals	0.06	3.34	2.78
ROIV Roivant Sciences	N/A	16.72	16.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MRNA Moderna	75.33%
NTRA Natera	99.90%
REGN Regeneron Pharmaceuticals	83.31%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
MRNA Moderna	10.80%
NTRA Natera	5.05%
REGN Regeneron Pharmaceuticals	6.97%
ROIV Roivant Sciences	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MRNA Moderna	4,700	399.24 million	356.12 million	Optionable
NTRA Natera	6,140	144.14 million	136.87 million	Optionable
REGN Regeneron Pharmaceuticals	15,410	102.96 million	95.78 million	Optionable
ROIV Roivant Sciences	721	722.32 million	658.76 million	Optionable

ROIV, MRNA, REGN, and NTRA Headlines

Recent News About These Companies

Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares of Company Stock

October 22 at 7:07 PM | marketbeat.com

Roivant’s TYK2/JAK inhibitor reduces need for steroids in inflammatory eye disease

October 22 at 7:15 AM | biospace.comB

Roivant Sciences Ltd. announces positive results in CLARITY-1 and CLARITY-2 phase 3 trials for brepocitinib

October 22 at 1:28 AM | msn.com

Stocks making the biggest moves midday: SpaceX, Meta Platforms, Super Micro Computer, Roivant Sciences & more

October 21 at 8:28 PM | cnbc.com

Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis Transcript

October 21 at 4:00 PM | seekingalpha.com

Roivant Sciences’ Brepocitinib Delivers Positive Phase III Uveitis Results

October 21 at 11:03 AM | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Shares Gap Up - Here's What Happened

October 21 at 11:00 AM | marketbeat.com

Roivant Sciences Says Brepocitinib Meets Primary Goal In Uveitis Trials; Shares Rise

October 21 at 10:27 AM | rttnews.com

Roivant Sciences stock surges on positive uveitis trial data

October 21 at 10:27 AM | finance.yahoo.com

Roivant Sciences' Brepocitinib Achieves Primary Endpoint in Two Phase 3 Trials in Non-Infectious Uveitis

October 21 at 10:27 AM | finance.yahoo.com

Roivant to seek label expansion for Lisraya in uveitis after late-stage trial win

October 21 at 10:27 AM | seekingalpha.com

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

October 21 at 7:00 AM | globenewswire.com

Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)

October 21 at 7:00 AM | globenewswire.com

Roivant Sciences (NASDAQ:ROIV) vs. Krystal Biotech (NASDAQ:KRYS) Head-To-Head Review

October 19, 2026 | americanbankingnews.com

Roivant Sciences (ROIV) Stock Looks Fully Priced After A 393% Run

October 18, 2026 | finance.yahoo.com

Roivant Sciences (ROIV) share price

October 16, 2026 | economictimes.indiatimes.com

Nobody wants to eat an AI cheeseburger

October 16, 2026 | msn.com

Roivant Sciences Ltd. $ROIV Stock Holdings Lowered by Assenagon Asset Management S.A.

October 16, 2026 | marketbeat.com

Analysts Conflicted on These Healthcare Names: ProKidney (PROK) and Roivant Sciences (ROIV)

October 15, 2026 | theglobeandmail.com

ROIV - Roivant Sciences Ltd.

October 15, 2026 | seekingalpha.com

Wolfe Research downgrades Roivant Sciences to peer perform from outperform

October 12, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ROIV, MRNA, REGN, and NTRA Company Descriptions

Moderna NASDAQ:MRNA

$202.63 -43.18 (-17.57%)

Closing price 10/22/2026 04:00 PM Eastern

Extended Trading

$195.40 -7.23 (-3.57%)

As of 10/22/2026 08:00 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Natera NASDAQ:NTRA

$401.37 -12.01 (-2.91%)

Closing price 10/22/2026 04:00 PM Eastern

Extended Trading

$401.32 -0.05 (-0.01%)

As of 10/22/2026 07:56 PM Eastern

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Regeneron Pharmaceuticals NASDAQ:REGN

$819.09 +13.42 (+1.67%)

Closing price 10/22/2026 04:00 PM Eastern

Extended Trading

$820.33 +1.24 (+0.15%)

As of 10/22/2026 07:58 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Roivant Sciences NASDAQ:ROIV

$37.45 +0.65 (+1.77%)

Closing price 10/22/2026 04:00 PM Eastern

Extended Trading

$37.95 +0.50 (+1.34%)

As of 10/22/2026 07:52 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ROIV, MRNA, REGN, and NTRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ROIV, MRNA, REGN, and NTRA Earnings

Compare Dividends

Latest ROIV, MRNA, REGN, and NTRA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ROIV, MRNA, REGN, and NTRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ROIV, MRNA, REGN, and NTRA Company Descriptions

Moderna NASDAQ:MRNA

Natera NASDAQ:NTRA

Regeneron Pharmaceuticals NASDAQ:REGN

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools